Neurology Department Research Activities
Contact Information
Protocol Description
A historical-controlled, multicenter, double-blind, randomized trial to assess the efficacy and safety of conversion to Lacosamide 400mg/day Monotherapy in subjects with partial-onset seizures. Protocol No: SP902
TYSABRI Global Observational Program in Safety (TYGRIS).
Protocol No:101-MS-402
Double-blind, placebo-controlled, randomized, parallel-group phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks.
Protocol No: C32322
Clinical Trial of Ceftriaxone in subjects with ALS.
Protocol No: CEF-ALS -2006
An International, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis.
Protocol No: EFC6260
A Phase 3 Randomized Rater-and-dose-blinded Study Comparing Two Annual Cycles of low- and high-dose atemtuzumab to three-times weekly interferon Beta-la (Rebif) in patients with RRMS who have relapsed on therapy.
Protocol No: CAMMS32400507-CARE MS II
Eligibility Criteria
TBD
